Sorrento and the University of Texas Medical Branch Collaborate for the Preclinical Testing of COVID-19 Therapeutic Candidates

 Sorrento and the University of Texas Medical Branch Collaborate for the Preclinical Testing of COVID-19 Therapeutic Candidates

Sorrento and the University of Texas Medical Branch Collaborate for the Preclinical Testing of COVID-19 Therapeutic Candidates

Shots:

  • Sorrento has entered into a research testing agreement with the UTMB for the preclinical testing of Sorrento’s therapeutic product candidates for COVID-19
  • The preclinical testing will be performed in Dr. Paessler’s laboratory at UTMB which Sorrento called “one of only two maximum containment laboratories on a university campus in the US and one of just a few such BSL4 laboratories currently operating in the US
  • Sorrento is currently conducting preclinical development of multiple candidates for COVID-19 across its platforms, including NK cell therapies, NAbs and COVIDTRAP to potentially inhibit the binding of SARS-CoV-2’s spike protein with ACE2 receptors, thereby preventing viral cell entry

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: Sorrento

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post